[18F]tetrafluoroborate as a PET tracer for the sodium/iodide symporter: the importance of specific activity
Open Access
- 22 April 2016
- journal article
- research article
- Published by Springer Nature in EJNMMI Research
- Vol. 6 (1) , 1-10
Abstract
[18F]BF4 −, the first 18F-labelled PET imaging agent for the sodium/iodide symporter (NIS), was produced by isotopic exchange yielding a product with limited specific activity (SA, ca. 1 GBq/μmol) posing a risk of sub-optimal target-to-background ratios (TBR) in PET images due to saturation of NIS in vivo. We sought to quantify this risk and to develop a method of production of [18F]BF4 − with higher SA. A new radiosynthesis of [18F]BF4 − was developed, involving reaction of [18F]F− with boron trifluoride diethyl etherate under anhydrous conditions, guided by 11B and 19F NMR studies of equilibria involving BF4 − and BF3. The SA of the product was determined by ion chromatography. The IC50 of [19F]BF4 − as an inhibitor of [18F]BF4 − uptake was determined in vitro using HCT116-C19 human colon cancer cells expressing the human form of NIS (hNIS). The influence of [19F]BF4 − dose on biodistribution in vivo was evaluated in normal mice by nanoPET imaging and ex vivo tissue counting. An IC50 of 4.8 μΜ was found in vitro indicating a significant risk of in vivo NIS saturation at SA achieved by the isotopic exchange labelling method. In vivo thyroid and salivary gland uptake decreased significantly with [19F]BF4 − doses above ca. 10 μg/kg. The new radiosynthesis gave high radiochemical purity (>99 %) and moderate yield (15 %) and improved SA (>5 GBq/μmol) from a starting activity of only 1.5 GBq. [18F]BF4 − produced at previously reported levels of SA (1 GBq/μmol) can lead to reduced uptake in NIS-expressing tissues in mice. This is much less likely in humans. The synthetic approach described provides an alternative for production of [18F]BF4 − at higher SA with sufficient yield and without need for unusually high starting activity of [18F]fluoride, removing the risk of NIS saturation in vivo even in mice. ISRCTN75827286 .Keywords
Funding Information
- Engineering and Physical Sciences Research Council
- GE Healthcare
- Guy's and St Thomas' NHS Foundation Trust
- Medical Research Council
- King’s College London Medical Engineering Centre
- Wellcome Trust
This publication has 26 references indexed in Scilit:
- Sodium Iodide Symporter for Nuclear Molecular Imaging and Gene Therapy: From Bedside to Bench and BackTheranostics, 2012
- Evaluation of [18F]-tetrafluoroborate as a potential PET imaging agent for the human sodium/iodide symporter in a new colon carcinoma cell line, HCT116, expressing hNISNuclear Medicine Communications, 2011
- Trafficking Macrophage Migration Using Reporter Gene Imaging with Human Sodium Iodide Symporter in Animal Models of InflammationJournal of Nuclear Medicine, 2010
- Bioimpedance spectroscopy for the estimation of body fluid volumes in miceAmerican Journal of Physiology-Renal Physiology, 2010
- Synthesis and biological evaluation of [18F]tetrafluoroborate: a PET imaging agent for thyroid disease and reporter gene imaging of the sodium/iodide symporterEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- A perspective view of sodium iodide symporter research and its clinical implicationsEuropean Journal of Endocrinology, 2006
- The role of chemistry in positron emission tomographyJournal of Chemical Education, 1988
- The Addition Compounds of Cyclic Ethers with Boron Trifluoride1,2Journal of the American Chemical Society, 1960
- Equilibria in the System Boron Trifluoride—Water at 25°Journal of the American Chemical Society, 1951
- Hydrolysis of Fluoboric Acid in Aqueous SolutionJournal of the American Chemical Society, 1948